Cencora, Inc. (NYSE:COR) Shares Acquired by KBC Group NV

KBC Group NV lifted its position in Cencora, Inc. (NYSE:COR) by 18.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 329,035 shares of the company’s stock after buying an additional 51,112 shares during the quarter. KBC Group NV owned approximately 0.17% of Cencora worth $73,928,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Concord Wealth Partners acquired a new stake in shares of Cencora during the third quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC increased its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after buying an additional 69 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Cencora during the 3rd quarter worth approximately $41,000. Modus Advisors LLC purchased a new position in Cencora in the 4th quarter valued at approximately $54,000. Finally, Carolina Wealth Advisors LLC grew its stake in shares of Cencora by 366.7% in the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock worth $60,000 after acquiring an additional 209 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Up 0.2 %

Shares of Cencora stock opened at $248.45 on Monday. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The company has a fifty day simple moving average of $237.51 and a 200-day simple moving average of $234.83. The stock has a market cap of $48.02 billion, a price-to-earnings ratio of 33.08, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $253.27.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Analyst Upgrades and Downgrades

COR has been the topic of several analyst reports. Leerink Partners reduced their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Robert W. Baird lifted their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Evercore ISI upped their target price on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $277.00.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,187 shares of company stock valued at $17,790,912. 15.80% of the stock is currently owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.